Results 161 to 170 of about 267,001 (338)

Methotrexate and the platelet count

, 1968
D. Ogston, A.A. Dawson, J F Philip
openalex   +2 more sources

A simple approach to biophysical profiling of blood cells in extranodal NK/T cell lymphoma patients using deep learning‐integrated image cytometry

BMEMat, EarlyView.
We developed a deep learning‐integrated image cytometry technique to profile biophysical attributes of blood cells from ENKTL patients. We demonstrate specific changes in cell size, eccentricity, and refractive index during treatment in a label‐free manner.
Seongcheol Park, Sang Eun Yoon, Youngho Song, Changyu Tian, Changi Baek, Hyunji Cho, Won Seog Kim, Seok Jin Kim, Soo‐Yeon Cho   +8 more
wiley   +1 more source

Lung Allografts in Dogs Treated with Methotrexate and Antilymphocyte Serum

, 1968
David A. Blumenstock, Henri P. Otte, O Grosjean, Martien A. Mulder   +3 more
openalex   +1 more source

Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. [PDF]

, 1979
Randal J. Kaufman, Peter C. Brown, Robert Schimke   +2 more
openalex   +1 more source

X‐ray controlled release strategy in cancer therapy

BMEMat, EarlyView.
A comprehensive review on the design principles and current strategies of X‐ray stimulated release systems in cancer therapy, focusing on the X‐ray responsive functional groups and materials as well as discussing the advantages and current challenges of X‐ray controlled release systems in cancer therapy.
Yiling Ruan, Hongxiang Huang, Huihui Liu, Jinglang Gong, Changjun Li, Xiaolian Sun   +5 more
wiley   +1 more source

Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study

Cancer Communications, EarlyView.
Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of aggressive non‐Hodgkin's lymphoma with distinct clinical and molecular heterogeneity. DLBCL that arises in extranodal organs is particularly linked to poor prognosis. This study aimed to determine the clinical and molecular characteristics of extranodal involvement (
Si‐Yuan Chen, Peng‐Peng Xu, Ru Feng, Guo‐Hui Cui, Li Wang, Shu Cheng, Rong‐Ji Mu, Hui‐Lai Zhang, Xiao‐Lei Wei, Yong‐Ping Song, Kai‐Yang Ding, Li‐Hua Dong, Zun‐Min Zhu, Shen‐Miao Yang, Xin Wang, Ting‐Bo Liu, Jian‐Da Hu, Xiao‐Yun Zheng, Ou Bai, Jing‐Yan Xu, Liang Huang, Wei Sang, Ke‐Qian Shi, Fan Zhou, Fei Li, Ai‐Bin Liang, Hui Zhou, Si‐Guo Hao, Hong‐Hui Huang, Bin Xu, Wen‐Bin Qian, Cai‐Xia Li, Zhi‐Ming Li, Chong‐Yang Wu, Xiao‐Bo Wang, Wen‐Yu Shi, Shu‐Ye Wang, Yu‐Yang Tian, Xi Zhang, Ke‐Shu Zhou, Li‐Juan Cui, Hui Liu, Huo Tan, Qing Leng, Dong‐Lu Zhao, Ting Niu, Wei‐Li Zhao   +46 more
wiley   +1 more source

PCFT‐Independent Cellular Uptake of Cyclic Cell‐Penetrating Peptide‐Conjugated Folic Acid

ChemBioChem, EarlyView.
Cell‐penetrating peptide (CPP)‐conjugated folic acid mediates efficient internalization of folic acid that is independent of the presence of proton‐coupled folate transporter (PCFT) on the intestinal cells. CPP‐conjugated folic acid demonstrates superior cellular uptake at all studied pH and in the presence of PCFT inhibitors and shows enhanced ...
Vineet Kumar Mishra, Rheal Towner, Juan Carlos Rodriguez‐Lecompte, Marya Ahmed   +3 more
wiley   +1 more source

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy [PDF]

, 1978
Joan M. Bull, Douglass C. Tormey, Shou-Hua Li, Paul P. Carbone, Geoffrey Falkson, Johannes Blom, Elliot Perlin, Richard Simon   +7 more
openalex   +1 more source

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, EarlyView.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source